Treatment of tumours
OwnerTomas Hagstrom, Peter Soderkvist +1inventors
InventorsTomas Hagstrom, Peter Soderkvist, Jan-Erling Backvall
Life of this patent
Estimating the term…
Loading patent…
OwnerTomas Hagstrom, Peter Soderkvist +1inventors
InventorsTomas Hagstrom, Peter Soderkvist, Jan-Erling Backvall
Estimating the term…
The present invention refers to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are -5-androstene-17-ol, androstane-17-ol-pregnane-17-ol or pregnane-17-ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3β,17-diol or androstane-3β-diol, an enzyme and a sulfotransferase to provide 5-androstene-17-ol-3β-sulfate or corresponding andros tane derivative (17-AEDS or 17-AADS); and mixing the 17-AEDS or 17-AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to peroxisome proliferators-activated receptor-(PPAR) is produced.
A steroid derivative selected from the group of compounds defined by formula (I) or (II) as shown below, wherein the only difference between said formulas is the bond between carbon number 5 and carbon number 6:
Use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment and/or prevention of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect.
A method of producing a medicament for the treatment and/or prevention of a benign and/or malignant tumour, comprising the steps of
Use of 17α-AEDS in the manufacture of a medicament, attenuating the effect through use of nuclear receptor ligands such as androgens, deltanoids, estrogens, retinoids, HNF-4, COUPTF, RXR, RAR, progestins, rexinoids, or cofactors of these or ligands to PPAR-α or δ.
Use of 17α-AEDS in the manufacture of an immunomodulating medicament, e.g. for the treatment and/or prevention of an inflammatory disease, such as rheumatoid arthritis, arthrosis, or inflammatory bowel disease, or a disease, such as multiple sclerosis or Guillain Barrés syndrome.
Dependencies are inferred from the claim text.